Skip to main content
padlock icon - secure page this page is secure

Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study

Buy Article:

$59.00 + tax (Refund Policy)

Björkstrand B, Rasmussen T, Remes K, Gruber A, Pelliniemi T-T, Johnsen HE. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study.

Eur J Haematol 2003: 70: 379–383. © Blackwell Munksgaard 2003. Abstract.

Multiple myeloma (MM) is considered to be an essentially incurable haematological malignant disease, probably because of the existence of resistant clonal precursor cell with self-renewal capacity. Recent data have indicated that the myeloma cell hierarchy includes circulating clonal memory B cells, which differ considerably from the classical end-stage plasma cells, infiltrating the bone marrow. The pathophysiological significance of these cells is unknown, but hypothetically they may serve as ‘sleeping’ myeloma stem cells responsible for and ‘feeding’ post-treatment relapse and progression. The present study evaluates the toxicity and feasibility of fludarabine, added to the VAD-induction regimen in MM, and investigates the effect on the myeloma cell hierarchy. Nineteen patients were randomised to receive either four cycles of VAD (n = 9) or two cycles of VAD, followed by two cycles of VAD combined with 5 days fludarabine 25 mg/m2/day i.v. (n = 10). Toxicity evaluation showed more profound neutropenia in the fludarabine-treated patients and two infectious episodes in each study arm: three were fever of unknown origin while one, in the fludarabine-arm, was a local skin infection at the insertion site of the central venous line. Nine of the fludarabine-treated patients responded to treatment (two complete remission, seven partial remission), compared with five responders (all PR) in the control-arm. The effects on the blood circulating myeloma compartments identified an increased reduction of CD19+ B cells and myeloma plasma cells in the fludarabine-arm. In conclusion, adding fludarabine to VAD induction in multiple myeloma is feasible and may be clinically effective by reducing the myeloma clone.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: B-cells; clonal cells; fludarabine; multiple myeloma; treatment

Document Type: Research Article

Affiliations: 1: Departments of Haematology at Huddinge University Hospital and 2: Herlev University Hospital, Herlev, Denmark; 3: Department of Medicine, University Central Hospital, Turku, Finland 4: Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden;

Publication date: June 1, 2003

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more